Payment overview · 2025
General Payments
$744.01
35 reported records · 10 companies
Healthcare provider profile · identity verified
Ronald S Luber
Allopathic & Osteopathic Physicians|Family Medicine · RICHBORO, PA · NPI 1598794968
Verified facts
What the public records show
CMS Open Payments records show Ronald S Luber received $744.01 in general payments during 2025 across 35 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $189.24 | 25.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.18 | 24.1% | 14 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $120.80 | 16.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.62 | 13.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.40 | 7.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.21 | 4.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.38 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.28 | 2.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.00 | 2.0% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $13.90 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.01 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $184.42 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $173.91 | 13 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $120.80 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $120.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $5.27 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $4.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 336 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 69 |
| Losartan Potassium | Losartan Potassium | 263 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 252 | 79 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 232 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 41 |
| Lisinopril | Lisinopril | 166 | 45 |
| Metformin Hcl | Metformin Hcl | 154 | 50 |
| Omeprazole | Omeprazole | 152 | 49 |
| Gabapentin | Gabapentin | 150 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 21 |
| Azithromycin | Azithromycin | 127 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 30 |
| Ibuprofen | Ibuprofen | 100 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 93 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 92 | 25 |
| Meloxicam | Meloxicam | 88 | 32 |
| Temazepam | Temazepam | 87 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 11 |
| Ozempic | Semaglutide | 85 | 15 |
| Jardiance | Empagliflozin | 81 | 14 |
| Simvastatin | Simvastatin | 77 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 19 |
| Clonidine Hcl | Clonidine Hcl | 74 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 20 |
| Amoxicillin | Amoxicillin | 69 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | suppressed |
| Clonazepam | Clonazepam | 60 | suppressed |
| Eliquis | Apixaban | 58 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 49 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Prednisone | Prednisone | 54 | 19 |
| Furosemide | Furosemide | 52 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 14 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 16 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Valsartan | Valsartan | 37 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | 11 |
| Glipizide | Glipizide | 31 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Alprazolam Odt | Alprazolam | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.01 · 35 records | Otsuka America Pharmaceutical, Inc. | BRIXADI, CAPLYTA, MOUNJARO, NUEDEXTA, NURTEC ODT, QULIPTA, REXULTI, SIMPONI ARIA, SUBLOCADE, Symbravo, TREMFYA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error